Johnson & Johnson (NYSE:JNJ) Shares Sold by Advisors Management Group Inc. ADV

Advisors Management Group Inc. ADV decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,996 shares of the company’s stock after selling 139 shares during the period. Advisors Management Group Inc. ADV’s holdings in Johnson & Johnson were worth $4,193,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in JNJ. ARS Wealth Advisors Group LLC raised its stake in shares of Johnson & Johnson by 1.3% in the 4th quarter. ARS Wealth Advisors Group LLC now owns 116,912 shares of the company’s stock worth $16,908,000 after buying an additional 1,507 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC boosted its stake in Johnson & Johnson by 6.9% during the fourth quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 18,500 shares of the company’s stock valued at $2,675,000 after buying an additional 1,200 shares in the last quarter. Burney Co. raised its position in Johnson & Johnson by 2.3% in the fourth quarter. Burney Co. now owns 37,175 shares of the company’s stock worth $5,376,000 after acquiring an additional 826 shares in the last quarter. Wolff Wiese Magana LLC lifted its holdings in Johnson & Johnson by 2.5% in the 4th quarter. Wolff Wiese Magana LLC now owns 3,832 shares of the company’s stock valued at $554,000 after acquiring an additional 92 shares during the last quarter. Finally, Apella Capital LLC boosted its position in shares of Johnson & Johnson by 1.5% during the 4th quarter. Apella Capital LLC now owns 24,335 shares of the company’s stock valued at $3,519,000 after purchasing an additional 348 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE JNJ opened at $147.78 on Friday. The company has a 50 day simple moving average of $148.86 and a 200-day simple moving average of $156.01. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The firm has a market capitalization of $355.79 billion, a price-to-earnings ratio of 21.39, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter last year, the business posted $2.66 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.36%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analyst Ratings Changes

Several analysts recently commented on JNJ shares. Bank of America reissued a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday, December 10th. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Finally, Morgan Stanley lifted their price target on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $174.71.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.